Payment overview · 2025
General Payments
$548.64
32 reported records · 11 companies
Healthcare provider profile · identity verified
Corey Lynn Diamond, MD
Allopathic & Osteopathic Physicians|Internal Medicine · JONESBORO, AR · NPI 1811983398
Verified facts
What the public records show
CMS Open Payments records show Corey Lynn Diamond, MD received $548.64 in general payments during 2025 across 32 reported records.
ABBVIE INC. accounted for 27.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Farxiga, Gemtesa, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 194 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $148.24 | 27.0% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $100.46 | 18.3% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $52.02 | 9.5% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.17 | 7.9% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $42.75 | 7.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.21 | 5.5% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $28.77 | 5.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.35 | 5.2% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $25.54 | 4.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $24.87 | 4.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $24.26 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $548.64 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $92.42 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $92.42 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $82.22 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $82.22 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $55.82 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $52.02 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $43.17 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $42.75 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $28.77 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.35 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $25.54 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $24.87 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $24.87 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $24.26 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.07 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $13.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 194 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 57 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
35 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
57 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
70 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
194 | 43 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 621 | 150 |
| Atorvastatin Calcium | Atorvastatin Calcium | 548 | 131 |
| Alprazolam | Alprazolam | 540 | 113 |
| Levothyroxine Sodium | Levothyroxine Sodium | 540 | 114 |
| Pantoprazole Sodium | Pantoprazole Sodium | 521 | 127 |
| Losartan Potassium | Losartan Potassium | 476 | 105 |
| Gabapentin | Gabapentin | 415 | 89 |
| Hydrochlorothiazide | Hydrochlorothiazide | 393 | 97 |
| Omeprazole | Omeprazole | 385 | 98 |
| Potassium Chloride | Potassium Chloride | 381 | 90 |
| Tramadol Hcl | Tramadol Hcl | 377 | 81 |
| Lisinopril | Lisinopril | 355 | 93 |
| Furosemide | Furosemide | 346 | 90 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 317 | 85 |
| Metformin Hcl | Metformin Hcl | 307 | 79 |
| Montelukast Sodium | Montelukast Sodium | 289 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 285 | 69 |
| Duloxetine Hcl | Duloxetine Hcl | 250 | 56 |
| Methylprednisolone | Methylprednisolone | 250 | 164 |
| Pravastatin Sodium | Pravastatin Sodium | 234 | 55 |
| Carvedilol | Carvedilol | 217 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 202 | 47 |
| Eliquis | Apixaban | 194 | 43 |
| Bupropion Xl | Bupropion Hcl | 188 | 32 |
| Simvastatin | Simvastatin | 185 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 183 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 182 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 181 | 33 |
| Trazodone Hcl | Trazodone Hcl | 176 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 172 | 56 |
| Ezetimibe | Ezetimibe | 161 | 45 |
| Tizanidine Hcl | Tizanidine Hcl | 159 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 155 | 52 |
| Cephalexin | Cephalexin | 147 | 86 |
| Allopurinol | Allopurinol | 146 | 36 |
| Clonazepam | Clonazepam | 143 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 143 | 59 |
| Meloxicam | Meloxicam | 140 | 46 |
| Buspirone Hcl | Buspirone Hcl | 129 | 32 |
| Lovastatin | Lovastatin | 129 | 31 |
| Amoxicillin | Amoxicillin | 116 | 80 |
| Celecoxib | Celecoxib | 113 | 30 |
| Alendronate Sodium | Alendronate Sodium | 109 | 34 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 108 | 26 |
| Donepezil Hcl | Donepezil Hcl | 107 | 28 |
| Ozempic | Semaglutide | 107 | 20 |
| Sertraline Hcl | Sertraline Hcl | 107 | 25 |
| Terazosin Hcl | Terazosin Hcl | 107 | 25 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 107 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 107 | 25 |
| Famotidine | Famotidine | 105 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 105 | 32 |
| Lorazepam | Lorazepam | 103 | 18 |
| Clonidine Hcl | Clonidine Hcl | 102 | 36 |
| Spironolactone | Spironolactone | 102 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 101 | 25 |
| Mirtazapine | Mirtazapine | 101 | 27 |
| Raloxifene Hcl | Raloxifene Hcl | 101 | 21 |
| Warfarin Sodium | Warfarin Sodium | 97 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 95 | 23 |
| Ondansetron Odt | Ondansetron | 93 | 48 |
| Pioglitazone Hcl | Pioglitazone Hcl | 93 | 24 |
| Propranolol Hcl | Propranolol Hcl | 90 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 88 | 22 |
| Januvia | Sitagliptin Phosphate | 86 | 15 |
| Prednisone | Prednisone | 86 | 38 |
| Diazepam | Diazepam | 85 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 82 | 19 |
| Ipratropium Bromide | Ipratropium Bromide | 82 | 25 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 81 | 20 |
| Nebivolol Hcl | Nebivolol Hcl | 81 | 19 |
| Baclofen | Baclofen | 80 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 75 | 24 |
| Pregabalin | Pregabalin | 74 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 73 | 15 |
| Methocarbamol | Methocarbamol | 72 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 71 | 43 |
| Finasteride | Finasteride | 70 | 16 |
| Jardiance | Empagliflozin | 70 | suppressed |
| Fenofibrate | Fenofibrate | 68 | 17 |
| Glipizide | Glipizide | 65 | 21 |
| Sucralfate | Sucralfate | 64 | 21 |
| Estradiol | Estradiol | 63 | 15 |
| Galantamine Er | Galantamine Hbr | 60 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 60 | 17 |
| Valacyclovir | Valacyclovir Hcl | 60 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 59 | suppressed |
| Azithromycin | Azithromycin | 58 | 51 |
| Promethazine Hcl | Promethazine Hcl | 58 | 19 |
| Farxiga | Dapagliflozin Propanediol | 57 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 57 | 12 |
| Memantine Hcl | Memantine Hcl | 56 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 55 | 15 |
| Meclizine Hcl | Meclizine Hcl | 53 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 42 |
| Paroxetine Hcl | Paroxetine Hcl | 51 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 50 | 12 |
| Clonidine | Clonidine | 50 | 12 |
| Atenolol | Atenolol | 49 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 47 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 34 |
| Ventolin Hfa | Albuterol Sulfate | 46 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 45 | suppressed |
| Glimepiride | Glimepiride | 45 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 45 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 11 |
| Diltiazem 24hr Er | Diltiazem Hcl | 44 | suppressed |
| Minoxidil | Minoxidil | 44 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | 12 |
| Xarelto | Rivaroxaban | 44 | suppressed |
| Fluconazole | Fluconazole | 43 | 32 |
| Myrbetriq | Mirabegron | 43 | suppressed |
| Nystatin | Nystatin | 41 | 20 |
| Sumatriptan Succinate | Sumatriptan Succinate | 41 | suppressed |
| Glipizide Er | Glipizide | 40 | suppressed |
| Sotalol | Sotalol Hcl | 40 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | suppressed |
| Topiramate | Topiramate | 37 | suppressed |
| Linzess | Linaclotide | 35 | 11 |
| Premarin | Estrogens, Conjugated | 35 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 34 | 14 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 34 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Nitroglycerin | Nitroglycerin | 32 | 25 |
| Constulose | Lactulose | 31 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 31 | 13 |
| Primidone | Primidone | 31 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 29 | suppressed |
| Cefdinir | Cefdinir | 28 | 23 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 28 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 26 |
| Lactulose | Lactulose | 27 | suppressed |
| Metolazone | Metolazone | 27 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 23 |
| Calcitriol | Calcitriol | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 20 |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Bumetanide | Bumetanide | 23 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Gemtesa | Vibegron | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Triazolam | Triazolam | 20 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Probenecid | Probenecid | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Nystop | Nystatin | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Enulose | Lactulose | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 11 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Procto-Med Hc | Hydrocortisone | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Trandolapril | Trandolapril | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 11 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $548.64 · 32 records | ABBVIE INC. | AREXVY, ELIQUIS, ENTRESTO, FARXIGA, GEMTESA, INSPIRE, KISUNLA, LEQVIO, MOUNJARO, NURTEC ODT, PAXLOVID, QULIPTA, REXULTI, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error